Cogent Biosciences, Inc. (COGT) NASDAQ

4.98

+0.1(+2.05%)

Updated at May 19 04:00PM

Currency In USD

Cogent Biosciences, Inc.

Address

200 Cambridge Park Drive

Cambridge, MA 02140

United States of America

Phone

617 945 5576

Sector

Healthcare

Industry

Biotechnology

Employees

205

First IPO Date

March 29, 2018

Key Executives

NameTitlePayYear Born
Mr. Andrew R. Robbins M.B.A.President, Chief Executive Officer & Director1.18M1976
Mr. Cole PinnowChief Commercial Officer443,1541975
Mr. John L. Green C.A., CPAChief Financial Officer & Principal Accounting Officer729,2371980
Dr. John Edward Robinson Ph.D.Chief Scientific Officer788,9011975
Dr. Jessica Sachs M.D.Chief Medical Officer814,1841975
Mr. Evan D. Kearns J.D.Chief Legal Officer & Corporate Secretary01980
Mr. Dana R. Martin Pharm.D.Senior Vice President of Medical Affairs & Chief Patient Officer0N/A
Ms. Erin SchellhammerChief People Officer0N/A
Ms. Christi WaarichSenior Director of Investor Relations0N/A
Mr. Brad BarnettChief Technology Officer0N/A

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.